vs
COASTAL FINANCIAL CORP（CCB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是COASTAL FINANCIAL CORP的1.5倍（$207.3M vs $138.0M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -5.8%），COASTAL FINANCIAL CORP自由现金流更多（$246.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -3.6%）
富达国民金融是美国财富500强企业，面向房地产与按揭行业提供产权保险及交割服务。2019年，其产权及房地产业务相关年营收约为84.69亿美元，是行业内具有领先地位的金融服务提供商。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CCB vs RARE — 直观对比
营收规模更大
RARE
是对方的1.5倍
$138.0M
营收增速更快
RARE
高出31.7%
-5.8%
自由现金流更多
CCB
多$346.9M
$-100.8M
两年增速更快
RARE
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $138.0M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 12.4% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | -5.8% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.84 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCBRARE
| Q4 25 | $138.0M | $207.3M | ||
| Q3 25 | $144.7M | $159.9M | ||
| Q2 25 | $119.4M | $166.5M | ||
| Q1 25 | $139.5M | $139.3M | ||
| Q4 24 | $146.5M | $164.6M | ||
| Q3 24 | $151.1M | $139.5M | ||
| Q2 24 | $135.3M | $147.0M | ||
| Q1 24 | $148.4M | $108.8M |
净利润CCBRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $13.6M | $-180.4M | ||
| Q2 25 | $11.0M | $-115.0M | ||
| Q1 25 | $9.7M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $13.5M | $-133.5M | ||
| Q2 24 | $11.6M | $-131.6M | ||
| Q1 24 | $6.8M | $-170.7M |
营业利润率CCBRARE
| Q4 25 | 12.4% | -54.7% | ||
| Q3 25 | 12.4% | -106.9% | ||
| Q2 25 | 12.0% | -64.8% | ||
| Q1 25 | 8.4% | -102.6% | ||
| Q4 24 | 11.7% | -74.3% | ||
| Q3 24 | 10.8% | -94.6% | ||
| Q2 24 | 11.1% | -79.1% | ||
| Q1 24 | 5.9% | -151.9% |
净利率CCBRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 9.4% | -112.8% | ||
| Q2 25 | 9.2% | -69.0% | ||
| Q1 25 | 7.0% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 8.9% | -95.7% | ||
| Q2 24 | 8.6% | -89.5% | ||
| Q1 24 | 4.6% | -156.8% |
每股收益（稀释后）CCBRARE
| Q4 25 | $0.84 | $-1.28 | ||
| Q3 25 | $0.88 | $-1.81 | ||
| Q2 25 | $0.71 | $-1.17 | ||
| Q1 25 | $0.63 | $-1.57 | ||
| Q4 24 | $0.95 | $-1.34 | ||
| Q3 24 | $0.97 | $-1.40 | ||
| Q2 24 | $0.84 | $-1.52 | ||
| Q1 24 | $0.50 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.0M | $-80.0M |
| 总资产 | $4.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCBRARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
股东权益CCBRARE
| Q4 25 | $491.0M | $-80.0M | ||
| Q3 25 | $475.3M | $9.2M | ||
| Q2 25 | $461.7M | $151.3M | ||
| Q1 25 | $449.9M | $144.2M | ||
| Q4 24 | $438.7M | $255.0M | ||
| Q3 24 | $331.9M | $346.8M | ||
| Q2 24 | $316.7M | $432.4M | ||
| Q1 24 | $303.7M | $140.3M |
总资产CCBRARE
| Q4 25 | $4.7B | $1.5B | ||
| Q3 25 | $4.6B | $1.2B | ||
| Q2 25 | $4.5B | $1.3B | ||
| Q1 25 | $4.3B | $1.3B | ||
| Q4 24 | $4.1B | $1.5B | ||
| Q3 24 | $4.1B | $1.5B | ||
| Q2 24 | $4.0B | $1.6B | ||
| Q1 24 | $3.9B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $254.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $246.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 178.3% | -48.6% |
| 资本支出强度资本支出/营收 | 6.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $436.4M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CCBRARE
| Q4 25 | $254.6M | $-99.8M | ||
| Q3 25 | $59.0M | $-91.4M | ||
| Q2 25 | $66.0M | $-108.3M | ||
| Q1 25 | $71.7M | $-166.5M | ||
| Q4 24 | $259.8M | $-79.3M | ||
| Q3 24 | $62.6M | $-67.0M | ||
| Q2 24 | $72.1M | $-77.0M | ||
| Q1 24 | $56.8M | $-190.7M |
自由现金流CCBRARE
| Q4 25 | $246.1M | $-100.8M | ||
| Q3 25 | $57.4M | $-92.7M | ||
| Q2 25 | $64.0M | $-110.7M | ||
| Q1 25 | $68.9M | $-167.8M | ||
| Q4 24 | $249.9M | $-79.5M | ||
| Q3 24 | $60.2M | $-68.6M | ||
| Q2 24 | $69.5M | $-79.0M | ||
| Q1 24 | $55.0M | $-193.9M |
自由现金流率CCBRARE
| Q4 25 | 178.3% | -48.6% | ||
| Q3 25 | 39.7% | -58.0% | ||
| Q2 25 | 53.6% | -66.5% | ||
| Q1 25 | 49.4% | -120.5% | ||
| Q4 24 | 170.6% | -48.3% | ||
| Q3 24 | 39.8% | -49.2% | ||
| Q2 24 | 51.3% | -53.7% | ||
| Q1 24 | 37.1% | -178.2% |
资本支出强度CCBRARE
| Q4 25 | 6.1% | 0.5% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 2.0% | 1.0% | ||
| Q4 24 | 6.8% | 0.1% | ||
| Q3 24 | 1.6% | 1.2% | ||
| Q2 24 | 1.9% | 1.4% | ||
| Q1 24 | 1.2% | 3.0% |
现金转化率CCBRARE
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | — | ||
| Q2 25 | 5.99× | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 6.22× | — | ||
| Q1 24 | 8.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
